Information Provided By:
Fly News Breaks for February 24, 2016
ATRC
Feb 24, 2016 | 07:43 EDT
Canaccord said AtriCure shares should be bought as its Q4 metrics were more bullish than implied by its Q4 earnings pre-announcement. The firm cited the company's double digit growth, clinical trials progress and new product launches. Canaccord reiterated its Buy rating and $28 price target on AtriCure shares.
News For ATRC From the Last 2 Days
There are no results for your query ATRC